The procedure was performed by Jason M. Scopp, MD, an orthopedic surgeon at Peninsula Orthopaedic Clinic in Salisbury, Maryland

Kfar Saba, Israel (ots/PRNewswire) - CartiHeal, developer of
Agili-C(TM), a proprietary implant for the treatment of cartilage
lesions in arthritic and non-arthritic joints, announced today the
first implantation of the Agili-C(TM) implant, as part of
Investigational Device Exemption (IDE) clinical study by Dr. Jason M.
Scopp, orthopedic surgeon and Director of Joint Preservation Center
at Peninsula Orthopaedic Clinic in Salisbury, Maryland.

The clinical study will involve a minimum of 250 study patients,
currently 241 patients have already been enrolled.

Peninsula Orthopaedic Clinic is one of 15 U.S. clinical sites
participating in this randomized and controlled IDE clinical study.
The primary study objective is to demonstrate the superiority of the
Agili-C(TM) implant over the current surgical standards of care:
microfracture and debridement in the treatment of large spectrum
cartilage defects.

"Our first patient was a 50-year-old male with moderate
osteoarthritis and with two large cartilage defects in a total
surface area of 6.8 cm[2]. One defect was located in the trochlea and
the second defect was located on the medial femoral condyle. The
patient was randomized to the Agili-C(TM) treatment arm and was
treated with 3 implants.

Patients who have cartilage defects are looking for options to not
only treat their pain, but also delay the need for joint
replacements," said Dr. Scopp. "I was very pleased that this patient
was randomized to the Agili-C group, as I believe it will provide the
solution he is seeking. As the Director of the Joint Preservation
Center at Peninsula Orthopaedic Associates, I am able to offer my
patients the state of the art techniques to preserve their joints and
maintain an active lifestyle. I am excited to enroll more patients
who meet the inclusion criteria."

CartiHeal's founder and CEO, Nir Altschuler, stated: "We are very
pleased that Dr. Scopp has joined our study. With 241 patients
already enrolled we are expecting to perform an interim analysis very
shortly, once the remaining 9 study patients are enrolled."

About CartiHeal

CartiHeal, a privately-held medical device company headquartered
in Israel and New Jersey, develops proprietary implants for the
treatment of cartilage and osteochondral defects in traumatic and
osteoarthritic joints.

CartiHeal's cell-free, off-the-shelf implant is CE marked for use
in cartilage and osteochondral defects. Agili-C(TM) has been
implanted in over 500 study patients with knee, ankle, and great toe
cartilage lesions in a series of clinical trials at leading centers
in Europe and Israel - treating a broad spectrum of cartilage
lesions, from single focal lesions to multiple and large defects in
osteoarthritic patients.

In the United States, the Agili-C(TM) implant is not available for
sale - it is an investigational device limited for use in the IDE
clinical study.

Contact:
www.cartiheal.com
info@cartiheal.com

Photo: https://mma.prnewswire.com/media/1010944/CartiHeal_Agili_C_
Dr_Scopp.jpg

Logo: https://mma.prnewswire.com/media/451231/CartiHeal_Logo.jpg

ots Originaltext: CartiHeal (2009) Ltd.
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: CartiHeal (2009) Ltd., übermittelt durch news aktuell